Blueprint Medicines Corporation
NASDAQ:BPMC
Overview | Financials
Company Name | Blueprint Medicines Corporation |
Symbol | BPMC |
Currency | USD |
Price | 104.89 |
Market Cap | 6,663,221,162 |
Dividend Yield | 0% |
52-week-range | 72.24 - 121.9 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Ms. Kathryn Haviland |
Website | https://www.blueprintmedicines.com |
An error occurred while fetching data.
About Blueprint Medicines Corporation
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD